Short answer
Denali Therapeutics Inc. (DNLI) filed an 8-K current report with the SEC on July 28, 2026 reporting Item 2.01 (Completion of Acquisition or Disposition of Assets). Denali completed sale of its Rare Pediatric Disease PRV on July 27, 2026.
Denali Therapeutics Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.01 · Completion of Acquisition or Disposition of Assets
- Denali completed sale of its Rare Pediatric Disease PRV on July 27, 2026
- $195.0 million gross proceeds received at closing, providing substantial non-dilutive liquidity
- PRV generated by March 2026 FDA approval of AVLAYAHTM for Hunter syndrome
- Proceeds may strengthen funding capacity for Denali’s pipeline and operations without equity issuance
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Denali Therapeutics Inc. 8-K filings
Get the next DNLI 8-K as it lands
Follow DNLI for push alerts, or ask the research agent what this filing means.